Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Direkt zur Navigaton springen.
Direkt zum Inhalt springen.

Navigation/Suche

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid Stoffw Microb

Horvath, K; Jeitler, K; Siering, U; Stich, AK; Skipka, G; Gratzer, TW; Siebenhofer, A.
Long-term effects of weight-reducing interventions in hypertensive patients: systematic review and meta-analysis.
ARCH INTERN MED. 2008; 168(6): 571-580. Doi: 10.1001/archinte.168.6.571 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

Führende Autor*innen der Med Uni Graz: Horvath Karl
Co-Autor*innen der Med Uni Graz: Jeitler Klaus; Siebenhofer-Kroitzsch Andrea
Altmetrics:
Dimensions Citations:
Plum Analytics:
Scite (citation analytics):
Abstract:: Weight loss is recommended in all major guidelines for antihypertensive therapy. We searched for randomized controlled trials investigating the effects of weight-reducing diets, pharmacologic substances, and invasive interventions for weight reduction on patient-relevant end points and blood pressure (BP) in patients with essential hypertension. No information on the effects on patient-relevant end points was available. Patients assigned to weight loss diets, orlistat, or sibutramine reduced their body weight more effectively than did patients in the usual care/placebo groups. Reduction of BP was higher in patients treated with weight loss diets (systolic BP [SBP]: weighted mean difference [WMD], -6.3 mm Hg; diastolic BP [DBP]: WMD, -3.4 mm Hg) or orlistat (SBP: WMD, -2.5 mm Hg; DBP: WMD, -2.0 mm Hg). Systolic BP increased with sibutramine treatment (WMD, 3.2 mm Hg). In patients with essential hypertension, therapy with a weight loss diet or orlistat resulted in reductions in body weight and BP. Although sibutramine treatment reduced body weight, it did not lower BP.
Find related publications in this database (using NLM MeSH Indexing): Appetite Depressants - therapeutic use; Blood Pressure - drug effects; Cyclobutanes - therapeutic use; Humans -; Hypertension - complications; Lactones - therapeutic use; Obesity - complications; Time Factors -; Treatment Outcome -; Weight Loss - drug effects